Bleeding complications during cardiac electronic device implantation in patients receiving antithrombotic therapy: is there any value of local tranexamic acid?

Table 3 Procedure related complications

Complications	All patients (n = 135)	Tranexamic acid (n = 52)	Control (n = 83)	P-value
Major bleeding complications, n (%)	20 (14.8)	3 (5.8)	17 (20.5)	0.024
Reoperation^a, n (%)	8 (5.9)	0 (0.0)	8 (9.6)	0.023
RBC transfusion^a, n (%)	15 (11.1)	2 (3.8)	13 (15.7)	0.047
Hemothorax^a, n (%)	1 (0.7)	0 (0.0)	1 (1.2)	1.0
Pericardial effusion^a, n (%)	3 (2.2)	1 (1.9)	2 (2.4)	1.0
Life-threatening bleed^a, n (%)	1 (0.7)	0 (0.0)	1 (1.2)	1.0
Pocket hematoma, n (%)	26 (19.3)	4 (7.7)	22 (26.5)	0.013
Pocket related infection, n (%)	1 (0.7)	0 (0.0)	1 (1.2)	1.0
Pneumothorax, n (%)	2 (1.4)	1 (1.9)	1 (1.2)	1.0

RBC red blood cells. ^aCounted events were presented (If a patient experienced multiple major bleeding complications, the clinical time course was reviewed to ensure that complications counted were distinctly separate events related to the procedure)